4DMT to Participate in Upcoming Investor Conferences
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that management will participate in several investor conferences in September 2026. The company will join the Wells Fargo 2026 Healthcare Conference on September 9, the Cantor Global Healthcare Conference on September 10 with a fireside chat at 10:20 a.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 with a fireside chat at 5:35 p.m. ET. Archived webcasts of these events will be available for up to one year in the Investors section of the 4DMT website.
Positive
- None.
Negative
- None.
Market Reaction – FDMT
Following this news, FDMT has gained 2.40%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $15.76.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September:
- Wells Fargo 2026 Healthcare Conference: Wednesday, September 9, 2026
- 2026 Cantor Global Healthcare Conference: Thursday, September 10, 2026; Fireside chat at 10:20 a.m. ET
- Morgan Stanley 24th Annual Global Healthcare Conference: Monday, September 14, 2026; Fireside chat at 5:35 p.m. ET
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and the second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
